Floatz logo

DEXKETOPROFEN

Anxiety

Istituti Clinici Scientifici Maugeri SpASmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Anxiety cohort.

Asset / SponsorPhaseRating
Cipralex
Wake Forest University Health Sciences
Phase 4BB
MIDAZOLAM
Theresa Jacob, PhD, MPH
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
RIVER Foundation
Phase 4BB
NEPENTHE
Istituti Clinici Scientifici Maugeri SpA
Phase 4BB
CITALOPRAM
Hannover Medical School
Phase 4BB

View all 34 →

Same molecule, other indications

DEXKETOPROFEN is also rated in:

migraine disorderDormant
BBB
Indicative ·
73 / 100
View asset →
migraine without auraDormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, HepatocellularDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →